LATEST NEWS IN PROSTATE CANCER
Breaking News: ERLEADA™ (apalutamide), a Next-Generation Androgen Receptor Inhibitor, Granted U.S. FDA Approval
Today, the US FDA approved Erleada (apalutamide), an androgen receptor inhibitor created by Janssen Pharmaceuticals for the treatment of men with non-metastatic, castration-resistant prostate cancer. Erleada was approved after a priority review of...
Bone Metastases and Prostate Cancer | An Interview with Dr. E. David Crawford by Prostatepedia
In this blog PCRI presents an interview from our contributing partner, Prostatepedia.
Prostatepedia spoke with Dr. E. David Crawford at length about bone metastases in prostate cancer. Here is the interview:
Sir Spheres for Liver Metastases from Prostate Cancer
Cancer that spreads outside the prostate gland is what makes prostate cancer dangerous. Metastatic prostate cancer cells cause malfunction by impeding normal function. Some organs, like lymph nodes for example, continue to function quite nicely, even if the degree of cancer spread is extensive. Lymph node spread, therefore, is the least dangerous form of prostate cancer metastases. At the other end of the spectrum is the liver, which is far less tolerant. The seriousness of bone metastases, the most common site of prostate cancer spread, lies about half way between that of node metastases and liver metastases.
Radium-223 (Alpharadin) A Novel Targeted Alpha-Emitter for Bone-Metastatic Castrate-Resistant Prostate Cancer
Radium-223 (or Alpharadin) is a new targeted alpha-emitting agent which has shown a prolongation of survival in castrate-resistant prostate cancer patients with bone-metastatic disease (5).